Mesoblast (MESO.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Nov5

Mesoblast's Chronic Lower Back Pain Phase III Study Data to be Discussed by FDA

00:02

Oct22

Mesoblast Limited Reports Ryoncil® Sales Growth and Plans for Key Trials

10:37

Oct8

Analyst McCarthy Gives Mesoblast Strong Buy Rating

16:21

Oct7

Shapiro Recommends Mesoblast Limited in Healthcare Sector

05:06

Oct6

Mesoblast Limited Reports 66% Growth in Ryoncil® Sales to $21.9 Million

23:26

Sep26

Mesoblast Product Designated as U.S. Origin, Tariff-Free

05:51

Schedules & Filings

Schedules

Filings

Aug28

Earning Release(EST)

FY2025 Q4 Earning Release (USD) Revenue 7.021 M, Net Income -27.1 M, EPS -0.2128

Feb26

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 1.578 M, Net Income -23.97 M, EPS -0.21

Aug28

Earning Release(EST)

FY2024 Q4 Earning Release (USD) Revenue 1.257 M, Net Income -27.71 M, EPS -0.2523

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change